HUTCHMED reports positive pivotal Phase 2 results for fanregratinib in FGFR2 fusion/rearrangement-positive intrahepatic cholangiocarcinoma, supporting its priority NDA review in China.
Written By: Shaik Yasmeen, PharmD
Reviewed By: Pharmacally Editorial Team
HUTCHMED has reported positive results from its pivotal Phase 2 registration study of fanregratinib (HMPL-453) in patients with previously treated advanced intrahepatic cholangiocarcinoma (ICC) harboring FGFR2 fusions or rearrangements. The findings will be presented at the ESMO Gastrointestinal Cancers Congress 2026 and support the company’s New Drug Application (NDA), which is currently under priority review by China’s National Medical Products Administration (NMPA).
The NDA, accepted in December 2025, seeks approval of fanregratinib for adults with advanced, metastatic, or unresectable FGFR2 fusion/rearrangement-positive ICC who have progressed after prior systemic therapy.
Fanregratinib Targets a Key Driver of Cholangiocarcinoma
Fanregratinib is an investigational oral, highly selective inhibitor of fibroblast growth factor receptors (FGFR) 1, 2, and 3. FGFR2 gene fusions and rearrangements occur in a subset of patients with intrahepatic cholangiocarcinoma and drive tumor growth through persistent activation of FGFR signaling.
Although targeted therapies have improved outcomes for this molecular subgroup, treatment options remain limited after progression on first-line chemotherapy and immunotherapy. Effective therapies capable of producing durable responses remain an important unmet need.
Pivotal Phase 2 Trial Demonstrated Rapid and Durable Responses
The single-arm, multicenter, open-label Phase 2 registration trial (NCT04353375) enrolled patients across 53 sites in China with advanced ICC harboring FGFR2 fusions or rearrangements. All participants had previously received at least one systemic treatment, including chemotherapy, while 72% had also received prior immunotherapy.
The study met its primary endpoint, with an independent review committee-assessed objective response rate (ORR) of 42.5% (95% CI: 30.0-53.6%).
Secondary efficacy endpoints further demonstrated meaningful clinical activity:
- Disease control rate (DCR): 83.9%
- Median time to response: 1.4 months
- Median duration of response (DoR): 6.9 months
- Median progression-free survival (PFS): 6.9 months
- Median overall survival (OS): 16.6 months
The rapid onset of response and durable disease control highlight fanregratinib’s potential to provide meaningful clinical benefit in a patient population with limited therapeutic options.
Safety Profile Remained Consistent with FGFR Inhibition
Fanregratinib demonstrated a manageable safety profile consistent with other selective FGFR inhibitors.
Grade 3 or higher treatment-related adverse events occurred in 48.3% of patients. The most frequently reported severe events included elevated liver enzymes and palmar-plantar erythrodysesthesia syndrome (PPES). Treatment discontinuation due to drug-related adverse events was low at 2.2%, and investigators reported no treatment-related deaths.
These findings suggest toxicity was generally manageable while maintaining prolonged treatment exposure.
Investigator Highlights Clinical Importance
Lead investigator Professor Jianming Xu of the Chinese PLA General Hospital noted that every patient enrolled had progressed after prior chemotherapy, and most had previously received immunotherapy, underscoring the difficult treatment landscape for advanced FGFR2-altered ICC.
He stated that the study’s objective response rate and survival outcomes support fanregratinib as a potent and selective oral targeted therapy that could expand treatment options for patients with this molecular subtype of cholangiocarcinoma.
Regulatory Path
The complete efficacy and safety dataset will be presented during the Rapid Oral Innovation Session at the ESMO Gastrointestinal Cancers Congress on July 4, 2026, in Munich, Germany.
With priority review already granted by the Chinese NMPA, fanregratinib has moved closer to becoming a new targeted treatment option for previously treated FGFR2 fusion/rearrangement-positive intrahepatic cholangiocarcinoma. Regulatory decisions in China and future global development will determine whether the therapy expands access to precision treatment for this rare and aggressive biliary tract cancer.
What This Means for Patients
Patients with advanced intrahepatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements often have limited treatment options after chemotherapy and immunotherapy stop working. The Phase 2 results suggest that fanregratinib may offer a new targeted treatment capable of shrinking tumors quickly and maintaining disease control for several months. If approved, it could provide an important precision medicine option for this genetically defined group of patients in China, with the potential for broader global development in the future.
Reference
About the Writer
Shaik Yasmeen (LinkedIn) is a Pharm.D graduate with interests in clinical pharmacy, pharmacovigilance, and medical writing. She has gained experience through hospital clinical postings, patient case reviews, case presentations, and literature evaluation. Passionate about evidence-based healthcare, she is committed to creating accurate and engaging medical content while continuously expanding her professional knowledge.